HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval84% confidence

Verified Clinical Benefit | Cancer Accelerated Approvals

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to Dr. Reddy's; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

Supporting Context

Therapeutic area
Hematology · Vitamin K
Sub-indication
General

Related signal: FDA Grants AP Status for Dr. Reddy's PHYTONADIONE ANDA215820

Source

View source document

Related Signal

Open signal — FDA Grants AP Status for Dr. Reddy's PHYTONADIONE ANDA215820
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.